Get the Stockscreener App
2.94
2.00%
-0.06
After Hours:
3.14
0.20
+6.80%
Curevac N V stock is traded at $2.94, with a volume of 398.27K.
It is down -2.00% in the last 24 hours and down -6.37% over the past month.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
See More
Previous Close:
$3.00
Open:
$3
24h Volume:
398.27K
Relative Volume:
0.53
Market Cap:
$659.48M
Revenue:
$58.17M
Net Income/Loss:
$-281.50M
P/E Ratio:
-1.8794
EPS:
-1.5643
Net Cash Flow:
$-349.78M
1W Performance:
-4.85%
1M Performance:
-6.37%
6M Performance:
-2.97%
1Y Performance:
-56.95%
1-Day Range:
$2.93
$3.11
1-Week Range:
$2.87
$3.215
52-Week Range:
$2.215
$6.93
Curevac N V Stock (CVAC) Company Profile
Curevac N V Stock (CVAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-08-23 | Initiated | SVB Securities | Outperform |
| Jan-19-23 | Upgrade | UBS | Neutral → Buy |
| Jan-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Hold |
| Jun-17-21 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Underperform |
| Apr-26-21 | Initiated | Guggenheim | Neutral |
| Dec-10-20 | Downgrade | Credit Suisse | Neutral → Underperform |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Sep-08-20 | Initiated | Credit Suisse | Neutral |
| Sep-08-20 | Initiated | Jefferies | Hold |
View All
Curevac N V Stock (CVAC) Latest News
Wall Street SWOT: CureVac stock navigates mRNA frontier amid restructuring - Investing.com
mRNA Vaccine and Therapeutics Market Global Report to 2035, with Profiles of Arcturus Therapeutics, BioNTech, CureVac, Ethris, Immorna, Moderna, Providence Therapeutics and Suzhou Abogen Biosciences - Yahoo Finance
Curefoods in talks to raise $40 million in Series D round of funding, eyes IPO in 18 months - Moneycontrol
C.H. Robinson Sells European Division in $1.5B Deal: Strategic Shift to North America - Tank Transport Trader
“CURED” screening highlights important LGBTQ+ issues - The Wayne Stater
Hood River Capital Management LLC Raises Stake in Caesars Entertainment, Inc. (NASDAQ:CZR) - Defense World
Caesars Entertainment, Inc. (NASDAQ:CZR) Shares Bought by Hsbc Holdings PLC - Defense World
Legendary 80s Band Makes Epic Comeback with First New Album in 16 Years—Spotted at Local Pub!Central - Central Recorder
Gurugram Based CurveAi, Raises Capital from a Swiss Family Office Fund - Business Standard
Chorus Limited Welcomes New COO Drew Davies - TipRanks
Gurugram Based CurveAi, Raises Capital from a Swiss Family Office Fund - ThePrint
Curbio settles fraud case; NAR partnership remains in place - HousingWire
CureVac's (CVAC) Market Outperform Rating Reiterated at JMP Securities - MarketBeat
CureVac (NASDAQ:CVAC) Shares Down 7.3% - MarketBeat
CureVac N.V.'s (NASDAQ:CVAC) Share Price Could Signal Some Risk - Simply Wall St
CureVac N.V. (CVAC) Stock: From Low to High in 52 Weeks - The InvestChronicle
Caesars Entertainment, Inc. (NASDAQ:CZR) Shares Bought by Prudential PLC - Defense World
CureVac (NASDAQ:CVAC) Shares Gap Down to $3.09 - MarketBeat
CureVac's cancer vaccine shows promise in early trial By Investing.com - Investing.com Australia
CureVac's cancer vaccine shows promise in early trial - Investing.com
CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress - AccessWire
CureVac's cancer vaccine shows promise in early trial By Investing.com - Investing.com UK
CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress - StockTitan
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program - AccessWire
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program - Yahoo Finance
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program - StockTitan
CureVac (NASDAQ:CVAC) Trading Up 9.9% - MarketBeat
CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress - AccessWire
CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress - Yahoo Finance
CureVac (NASDAQ:CVAC) Shares Down 3.3% - MarketBeat
CUREVAC : Deutsche Bank reiterates its Neutral rating - Marketscreener.com
CureVac (NASDAQ:CVAC) Short Interest Down 10.0% in August - MarketBeat
CUREVAC : A beneficial deal - Marketscreener.com
Simtra BioPharma Solutions ernennt Dr. Lidia Serina zum Head of Development Services - GlobeNewswire Inc.
News Flash: 8 Analysts Think CureVac N.V. (NASDAQ:CVAC) Earnings Are Under Threat - Yahoo Finance
CUREVAC : Much noise at CureVac, overshadowing recent positive pipeline progress - Marketscreener.com
CureVac NV (XTER:5CV) Inventory-to-Revenue : 0.92 (As of Jun. 2024) - GuruFocus.com
CVACCureVac N.V. Latest Stock News & Market Updates - StockTitan
CureVac Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
CureVac NV (MEX:CVAC) Inventory-to-Revenue : 2.09 (As of Mar. 2024) - GuruFocus.com
CureVac NV (MEX:CVAC) Other Current Liabilities : MXN1,751 Mil (As of Mar. 2024) - GuruFocus.com
CVAC (CureVac NV) Operating Margin % : -600.01% (As of Mar. 2024) - GuruFocus.com
CureVac (NASDAQ:CVAC) PT Lowered to $16.00 at JMP Securities - MarketBeat
CureVac (NASDAQ:CVAC) Short Interest Down 16.2% in July - MarketBeat
CureVac (NASDAQ:CVAC) Price Target Cut to $16.00 by Analysts at JMP Securities - Defense World
CureVac Earnings: Early-Stage Pipeline Makes Progress; GSK Agreement and Reorganization Extend Cash - Morningstar
CureVac (NASDAQ:CVAC) Shares Down 2.1% - MarketBeat
CureVac’s Rising Revenues Met With Increased Losses - TipRanks
CureVac begins next phase in glioblastoma vaccine trial By Investing.com - Investing.com Canada
CureVac begins next phase in glioblastoma vaccine trial By Investing.com - Investing.com Australia
CureVac begins next phase in glioblastoma vaccine trial - Investing.com India
Curevac N V Stock (CVAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):